Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Published:2021-09 Issue:9 Volume:19 Page:1079-1109
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Brown Patrick A.¹,Shah Bijal²,Advani Anjali³,Aoun Patricia⁴,Boyer Michael W.⁵,Burke Patrick W.⁶,DeAngelo Daniel J.⁷,Dinner Shira⁸,Fathi Amir T.⁹,Gauthier Jordan¹⁰,Jain Nitin¹¹,Kirby Suzanne¹²,Liedtke Michaela¹³,Litzow Mark¹⁴,Logan Aaron¹⁵,Luger Selina¹⁶,Maness Lori J.¹⁷,Massaro Stephanie¹⁸,Mattison Ryan J.¹⁹,May William²⁰,Oluwole Olalekan²¹,Park Jae²²,Przespolewski Amanda²³,Rangaraju Sravanti²⁴,Rubnitz Jeffrey E.²⁵,Uy Geoffrey L.²⁶,Vusirikala Madhuri²⁷,Wieduwilt Matthew²⁸,Lynn Beth²⁹,Berardi Ryan A.²⁹,Freedman-Cass Deborah A.²⁹,Campbell Mallory²⁹

Affiliation:

1. 1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

2. 2Moffitt Cancer Center;

3. 3Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

4. 4City of Hope National Medical Center;

5. 5Huntsman Cancer Institute at the University of Utah;

6. 6University of Michigan Rogel Cancer Center;

7. 7Dana-Farber/Brigham and Women’s Cancer Center;

8. 8Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

9. 9Massachusetts General Hospital Cancer Center;

10. 10Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

11. 11The University of Texas MD Anderson Cancer Center;

12. 12Duke Cancer Institute;

13. 13Stanford Cancer Institute;

14. 14Mayo Clinic Cancer Center;

15. 15UCSF Helen Diller Family Comprehensive Cancer Center;

16. 16Abramson Cancer Center at the University of Pennsylvania;

17. 17Fred & Pamela Buffett Cancer Center;

18. 18Yale Cancer Center/Smilow Cancer Hospital;

19. 19University of Wisconsin Carbone Cancer Center;

20. 20UCLA Jonsson Comprehensive Cancer Center;

21. 21Vanderbilt-Ingram Cancer Center;

22. 22Memorial Sloan Kettering Cancer Center;

23. 23Roswell Park Comprehensive Cancer Center;

24. 24O'Neal Comprehensive Cancer Center at UAB;

25. 25St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

26. 26Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

27. 27UT Southwestern Simmons Comprehensive Cancer Center;

28. 28UC San Diego Moores Cancer Center; and

29. 29National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/19/9/article-p1079.xml

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of FOXO3 (rs17069665) gene polymorphism and childhood acute lymphoblastic leukemia in Egypt;Gene Reports;2024-12

2. Development and validation of a nomogram for individualizing fall risk in patients with hematologic malignancies;Geriatric Nursing;2024-11

3. Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients;Leukemia Research;2024-10

4. Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL);Current Treatment Options in Oncology;2024-08-05

5. Minimal residual disease: premises before promises;Biology & Philosophy;2024-08